Previous 10 | Next 10 |
home / stock / amlx / amlx articles
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investors who suffered substant...
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amylyx Pharmaceuticals, Inc. ("Amylyx" or t...
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own securities of Amylyx Pharmaceuticals, Inc. (NASDAQ...
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amylyx...
LOS ANGELES, March 25, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on...
SAN DIEGO, March 25, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commen...
SAN FRANCISCO, March 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investors who suffered substant...
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons a...
NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amyly...
News, Short Squeeze, Breakout and More Instantly...
Amylyx Pharmaceuticals Inc. Company Name:
AMLX Stock Symbol:
NASDAQ Market:
Amylyx Pharmaceuticals Inc. Website:
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The conference is being conducted in-person in Miam...
2024-05-10 16:30:03 ET H.C. Wainwright analyst issues BUY recommendation for AMLX on May 10, 2024 02:01PM ET. The previous analyst recommendation was Buy. AMLX was trading at $1.775 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...